Literature DB >> 6637363

The value of variables of disseminated intravascular coagulation in the diagnosis of adult respiratory distress syndrome.

J Modig, T Borg, G Wegenius, L Bagge, T Saldeen.   

Abstract

UNLABELLED: In an investigation on 19 patients with traumatic (n = 11) and septic (n = 8) shock, at risk of developing adult respiratory distress syndrome (ARDS), various coagulation and fibrinolysis variables and also blood gases and chest x-ray were monitored. Eight patients developed ARDS - two after traumatic shock and six following septic shock. LABORATORY
FINDINGS: the conventional disseminated intravascular coagulation variables (fibrinogen, platelet counts, activated partial thromboplastin time, ethanol gelation test, thrombotest, normotest and fibrin degradation products) could not discriminate between ARDS and non-ARDS patients, but showed an essentially similar reaction pattern in these two groups. Antithrombin-III and plasminogen levels were significantly lower in patients with ARDS, while factor VIII-related antigen levels were significantly higher in ARDS than in non-ARDS patients. CLINICAL DATA: patients with septic shock run a significantly greater risk of developing ARDS (6 of 8) than those with traumatic shock (2 of 11; P less than 0.02). Furthermore, the onset of ARDS after septic shock seems to occur in a more rapid way, while ARDS following traumatic shock develops more gradually. Early ventilator treatment with positive end expiratory pressure counteracts the classical radiographic picture of ARDS with bilateral alveolar densities.

Entities:  

Mesh:

Year:  1983        PMID: 6637363     DOI: 10.1111/j.1399-6576.1983.tb01970.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  1 in total

1.  Early elevation of plasma von Willebrand factor antigen in pediatric acute lung injury is associated with an increased risk of death and prolonged mechanical ventilation.

Authors:  Heidi R Flori; Lorraine B Ware; Meredith Milet; Michael A Matthay
Journal:  Pediatr Crit Care Med       Date:  2007-03       Impact factor: 3.624

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.